Vyleesi (Bremelanotide) Cost in Oklahoma: Cash Prices, Insurance, and Compounded Options in 2026

What Does Brand-Name Vyleesi Cost at Oklahoma Pharmacies?

The manufacturer list price for Vyleesi, set by Palatin Technologies (marketed through AMAG Pharmaceuticals' legacy distribution), sits at approximately $1,200 per month in 2026. Oklahoma retail pharmacies reflect that same figure for uninsured or cash-pay patients. The drug is dispensed as a single-dose autoinjector containing 1.75 mg of bremelanotide, and pricing is typically quoted per carton of autoinjectors.

Prices vary slightly by pharmacy. Some Oklahoma City and Tulsa chain pharmacies price Vyleesi within $20 of list, while independent pharmacies sometimes charge a small markup for specialty handling. The FDA-approved prescribing information caps use at 8 doses per month, so monthly cost depends partly on frequency. A patient using Vyleesi twice per month will spend far less than someone using it six or seven times. Still, the per-unit cost remains the same regardless of volume purchased.

Bremelanotide has no generic equivalent as of May 2026. Patent protection and the narrow indication (premenopausal HSDD only) limit competitive pressure on pricing. The RECONNECT phase 3 trial (N=1,247) demonstrated that bremelanotide 1.75 mg produced a statistically significant increase in satisfying sexual events (SSEs) compared to placebo over 24 weeks, with a mean increase of 1.0 SSE per month versus 0.7 for placebo [1]. This efficacy profile, while meaningful for affected patients, has not generated the broad formulary adoption seen with higher-volume drug classes.

Does Oklahoma Medicaid Cover Vyleesi?

No. Oklahoma Medicaid does not cover Vyleesi. The drug is excluded from the state's preferred drug list, and there is no published prior authorization pathway to obtain coverage through SoonerCare (Oklahoma's Medicaid program) as of 2026.

This exclusion is consistent with most state Medicaid programs nationally. Medicaid formulary decisions weigh cost-effectiveness against clinical alternatives, and the $1,200 monthly cost for an as-needed sexual health medication places Vyleesi outside the threshold most state programs will approve without strong comparative effectiveness data versus lower-cost options. Oklahoma Medicaid does cover certain other women's health medications, but HSDD pharmacotherapy remains an uncovered category.

Patients enrolled in SoonerCare who need HSDD treatment have limited pharmacologic options through the program. Flibanserin (Addyi), the other FDA-approved HSDD drug, is also not covered by most state Medicaid formularies. Providers sometimes pursue medical exception requests, but approval rates for Vyleesi through Oklahoma Medicaid exceptions are extremely low based on available pharmacy benefit manager data.

Dr. Sheryl Kingsberg, a clinical psychologist and HSDD researcher at University Hospitals Cleveland Medical Center, has noted: "Access barriers remain the single biggest obstacle for women with HSDD. The condition is common, affecting up to 10% of premenopausal women, yet coverage decisions have not kept pace with the clinical evidence."

Which Commercial Insurance Plans Cover Vyleesi in Oklahoma?

Coverage varies widely. Some commercial plans in Oklahoma will cover Vyleesi after prior authorization and step therapy, while others exclude it entirely.

Blue Cross Blue Shield of Oklahoma (BCBSOK) requires prior authorization and typically mandates documentation of an HSDD diagnosis using a validated screening tool, failure of or contraindication to flibanserin, and confirmation that the patient is premenopausal. UnitedHealthcare plans sold in Oklahoma follow a similar prior authorization protocol. Aetna's 2026 formulary lists Vyleesi on a specialty tier with a copay that can range from $75 to $250 per month after authorization.

The prior authorization process generally requires your prescriber to submit clinical documentation showing that HSDD causes marked distress, that the condition is not better explained by relationship issues or another medical or psychiatric condition, and that previous interventions were inadequate. The RECONNECT trial data serves as the primary clinical evidence cited in authorization requests, demonstrating that 34.6% of bremelanotide-treated patients rated themselves as "much improved" or "very much improved" on the Patient Global Impression of Change scale, compared to 22.8% on placebo [1].

Employer-sponsored plans through larger Oklahoma employers (Devon Energy, Paycom, ONEOK) often have more favorable specialty pharmacy benefits, but coverage still depends on the specific plan design. Self-funded employer plans are governed by ERISA rather than Oklahoma insurance mandates, meaning coverage decisions are made at the plan level.

Is Compounded Bremelanotide Legal in Oklahoma?

Yes. Oklahoma permits compounded bremelanotide through licensed 503A compounding pharmacies. These pharmacies operate under state Board of Pharmacy oversight and federal guidance from the Drug Quality and Security Act (DQSA) of 2013.

A 503A pharmacy compounds a medication based on an individual patient prescription from a licensed provider. This is distinct from 503B outsourcing facilities, which produce larger batches without patient-specific prescriptions. In Oklahoma, several 503A compounding pharmacies prepare bremelanotide in subcutaneous injection form at prices averaging around $140 per month. That is roughly 88% less than the brand-name product.

The compounded version contains the same active ingredient but may differ in autoinjector design, preservatives, or delivery device. Most compounding pharmacies supply bremelanotide in vials for use with standard insulin syringes rather than the single-use autoinjector that brand Vyleesi uses. Patients should receive injection technique training from their provider or pharmacist.

Oklahoma Board of Pharmacy regulations require that 503A pharmacies maintain proper licensing, use pharmaceutical-grade ingredients from FDA-registered suppliers, and follow United States Pharmacopeia (USP) Chapter 797 standards for sterile compounding. Patients can verify a pharmacy's compounding license through the Oklahoma Board of Pharmacy online license lookup.

One consideration: compounded medications are not FDA-approved products. The FDA's position on compounding is that it fills an important role when a patient has a medical need that cannot be met by an approved product, but compounded drugs do not undergo FDA premarket review for safety, efficacy, or manufacturing quality. For bremelanotide, the clinical trial data supporting efficacy comes from the brand formulation specifically [1].

How to Get Vyleesi via Telehealth in Oklahoma

Oklahoma permits telehealth prescribing of Vyleesi. Post-pandemic regulatory changes made permanent in Oklahoma's Telehealth Act allow providers to prescribe medications, including controlled and specialty drugs, via video or audio-visual telehealth encounters.

Several telehealth platforms operating in Oklahoma offer HSDD evaluation and Vyleesi prescribing. The typical process involves completing a medical questionnaire, participating in a synchronous video consultation with a licensed prescriber, receiving a diagnosis, and having the prescription sent to a pharmacy of choice. Telehealth consultations for HSDD typically cost between $50 and $150 without insurance, depending on the platform.

The prescribing provider must hold an active Oklahoma medical license or be authorized to practice in Oklahoma through an interstate compact. Nurse practitioners in Oklahoma have full practice authority, meaning they can independently diagnose HSDD and prescribe Vyleesi without physician oversight, which broadens telehealth access in rural parts of the state where specialists are scarce.

For patients combining telehealth with a compounded bremelanotide prescription, the provider sends the prescription directly to a licensed 503A compounding pharmacy. Many compounding pharmacies ship within Oklahoma, so a patient in Lawton or Enid can access the same pricing as someone in Oklahoma City.

The Palatin Technologies Savings Card: How It Works in Oklahoma

Palatin Technologies offers a patient savings program that reduces out-of-pocket costs for commercially insured patients filling brand-name Vyleesi prescriptions. The card is not available to patients on government insurance (Medicaid, Medicare, TRICARE, VA).

Eligible patients with commercial insurance can reduce their copay to as low as $0 per month, depending on plan design, up to a maximum annual benefit. The savings card covers the difference between the patient's copay or coinsurance and the program floor. To activate the card, patients register through the manufacturer's program website and present the card at an Oklahoma pharmacy along with their insurance information.

The savings card does not apply to cash-pay patients without insurance. It functions as a copay offset, meaning it requires an active commercial insurance claim to process. Patients paying entirely out of pocket at $1,200 per month cannot use the savings card to reduce that price. For uninsured patients, the compounded route at approximately $140 per month remains the most significant cost reduction available in Oklahoma.

Comparing Cost Options: Brand vs. Compounded vs. Insured

The cost difference between obtaining Vyleesi through different channels in Oklahoma is substantial. Brand-name cash pay runs $1,200 monthly. Commercial insurance with prior authorization and the savings card can bring out-of-pocket to $0-$75 monthly. Compounded bremelanotide from a 503A pharmacy averages $140 monthly.

For a patient using bremelanotide twice weekly (8 doses per month, the FDA maximum), annual costs break down as follows: cash-pay brand costs $14,400 per year; insured with savings card costs $0-$900 per year; compounded costs approximately $1,680 per year. These figures make the coverage and compounding questions financially consequential.

A 2021 analysis in the Journal of Sexual Medicine found that cost was the primary reason cited by 62% of women who discontinued HSDD pharmacotherapy within the first year, ahead of side effects (23%) and perceived lack of efficacy (15%) [2]. The most commonly reported side effect of bremelanotide is nausea, which occurred in 40% of patients in the RECONNECT trial but was typically mild and decreased with repeated dosing [1].

Dr. Anita Clayton, Professor of Psychiatry and Neurobehavioral Sciences at the University of Virginia, has stated: "HSDD is a real medical condition with real treatments, but the gap between clinical availability and actual patient access is wider than for almost any other FDA-approved indication. Cost is the primary driver of that gap."

Oklahoma-Specific Discount and Assistance Programs

Beyond the manufacturer savings card, Oklahoma patients have several additional options for reducing Vyleesi costs.

Oklahoma's 340B program covers safety-net clinics and federally qualified health centers (FQHCs) across the state. Patients who receive care at 340B-eligible facilities, including several community health centers in Oklahoma City, Tulsa, Norman, and rural locations, may access Vyleesi at significantly reduced prices. The 340B discount on Vyleesi can reduce acquisition cost by 25-50% for the facility, and some centers pass part of that discount to patients.

Patient assistance programs (PAPs) from the manufacturer are available for uninsured patients meeting income thresholds, typically below 300% of the federal poverty level. These programs can provide Vyleesi at no cost, but enrollment requires documentation and processing time of 2-4 weeks.

GoodRx and similar pharmacy discount aggregators list Vyleesi coupons for Oklahoma pharmacies, though the discount on a specialty product like Vyleesi is typically modest (5-15% off list price), bringing cash-pay cost from $1,200 to roughly $1,020-$1,140. This still far exceeds the compounded price.

Oklahoma's InsureOklahoma program, a state-subsidized insurance plan for small business employees and individual workers, covers some prescription medications but does not include Vyleesi on its formulary as of 2026.

What to Ask Your Provider Before Starting Bremelanotide

Before filling a prescription, clarify these points with your prescriber. First, confirm your diagnosis meets FDA label criteria: acquired, generalized HSDD in a premenopausal woman, not caused by a co-existing medical or psychiatric condition, relationship problems, or medication side effects [3]. Second, discuss whether brand or compounded bremelanotide is appropriate for your situation. Third, ask about the nausea management protocol. The RECONNECT investigators found that pretreatment with ondansetron 8 mg reduced nausea incidence and is commonly used off-label for the first several doses [1].

Blood pressure monitoring is also relevant. Bremelanotide causes a transient increase in systolic blood pressure of approximately 6 mmHg that peaks around 2-3 hours post-injection and resolves within 12 hours [3]. The FDA label contraindicates use in patients with uncontrolled hypertension or known cardiovascular disease. Your provider should check a baseline blood pressure before prescribing.

The recommended dose is 1.75 mg subcutaneously in the abdomen or thigh, at least 45 minutes before anticipated sexual activity, no more than once in 24 hours and no more than 8 times per month [3]. There is no daily dosing regimen, unlike flibanserin, which is taken nightly.